Abstract：
Tuberculosis (TB) continues to be a global challenge. Reducing the duration of TB treatment for drug-sensitive TB (DSTB) has direct and distinct advantages. We ventured into the aspect of utilizing linezolid as a pivotal drug in shortening therapy in DSTB. Linezolid has gained prominence as it is faring well in resistant TB management. Only a few studies use the strategy of Linezolid in DS-TB but it seems a lucrative approach, the bactericidal effects have been reported favourably in the studies. There have been concerns about the potential adverse drug effects of Linezolid reported but clinical trials have demonstrated safety and tolerability when administered for shorter periods. If the safety and efficacy of giving Linezolid for a shorter period along with standard drugs for DSTB is established it could lead to newer avenues using Linezolid for shortening the duration of treatment for DSTB as an alternative to treat DSTB.
摘要：
结核病（TB）仍然是一个全球性的挑战。减少药物敏感性结核病（DSTB）的结核病治疗持续时间具有直接和明显的优势。我们冒险利用利奈唑胺作为DSTB缩短治疗的关键药物。利奈唑胺在耐药结核病管理方面表现良好，因此已获得突出地位。只有少数研究在DS-TB中使用利奈唑胺的策略，但这似乎是一种有利可图的方法，在研究中已经报道了良好的杀菌效果。有人担心利奈唑胺的潜在不良反应，但临床试验已经证明了短期给药的安全性和耐受性。如果确定了在较短时间内给予利奈唑胺以及DSTB的标准药物的安全性和有效性，则可能会导致使用利奈唑胺缩短DSTB治疗持续时间的新途径，以替代治疗DSTB。
